Inspira Technologies Reports Full Year 2025 Financial Results and Provides Business Updates
Rhea-AI Summary
Inspira (Nasdaq: IINN) reported full-year 2025 results and business updates on March 26, 2026, highlighting clinical validation and early commercial traction for the INSPIRA ART100 system.
Key points: $289k 2025 revenue from initial deployments, $49.5M binding purchase orders secured in mid-2025 expected to convert to 2026 revenue, R&D $7.496M, operating loss $13.22M, cash $3.159M at year-end, and a subsequent $4.75M registered direct offering boosting liquidity.
Positive
- Binding purchase orders of $49.5M secured in mid-2025
- Initial commercial revenue of $289k from ART100 deployments
- Completed registered direct offering raising $4.75M
- U.S. patent approval extending core technology protection through 2043
Negative
- Net loss widened to $13.22M in 2025
- Cash and equivalents declined to $3.159M at year-end 2025
- Total operating expenses increased to $13.623M for 2025
Market Reaction – IINN
Following this news, IINN has declined 12.02%, reflecting a significant negative market reaction. Argus tracked a trough of -17.5% from its starting point during tracking. Our momentum scanner has triggered 7 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.45. This price movement has removed approximately $3M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
IINN was down 2.03% with at least two medical-device peers (e.g., MODD, IRIX) also down (median about -8.8%), pointing to broader Healthcare/MedTech pressure rather than a purely stock-specific move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 01 | H1 2025 earnings | Positive | -6.3% | Reported first revenues, large ART100 orders, HYLA accuracy and higher expenses. |
| Mar 11 | FY 2024 earnings | Positive | -0.1% | FY 2024 results with ART100 clearance, HYLA data and reduced operating expenses. |
Earnings and financial updates have historically been followed by modest negative moves, with an average same-tag reaction of about -3.18%, indicating cautious responses even to operational progress.
Over the past year, Inspira’s earnings updates have combined operational milestones with continued losses. The 2024 full-year report highlighted FDA 510(k) clearance for ART100, HYLA accuracy data, and operating expenses of $11.27M, with net loss of $11.05M and cash of $5.78M. The H1 2025 update added $49.5M in ART100 purchase orders, first revenues of $289,000, HYLA accuracy of 97.35%, and higher expenses of $7.2M. Today’s full-year 2025 results extend that theme of commercial traction alongside rising costs and losses.
Historical Comparison
Past year earnings updates prompted average moves of -3.18%, suggesting investors have typically reacted cautiously to Inspira’s financial reports.
Across FY 2024, H1 2025 and now FY 2025, Inspira’s earnings updates trace a path from ART100 clearance to first commercial revenues and sizeable purchase orders, while expenses and net losses continue to rise.
Regulatory & Risk Context
Inspira has an active Form F-3 shelf filed on 2025-11-25, allowing issuance of up to $75,000,000 of ordinary shares, warrants and units over time, one component of its broader financing flexibility alongside past registered direct offerings and ATM capacity.
Market Pulse Summary
The stock is dropping -12.0% following this news. A negative reaction despite the reported progress would fit the pattern of cautious responses to prior earnings, which averaged about -3.18% post-release. Investors may be focusing on the widened net loss of $13.220M, higher operating expenses of $13.623M, and a year-end cash balance of $3.159M despite new revenues of $289,000. The recent $4.75M raise and existing $75M shelf also keep capital-raising overhang in view.
Key Terms
registered direct offering financial
equity-linked liabilities financial
AI-generated analysis. Not financial advice.
Company Demonstrates Clinical Validation and Early Commercial Traction Toward 2026 Revenue Scale
RA'ANANA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced its financial results for the full year ended December 31, 2025, and provided a corporate update.
Dagi Ben-Noon, Chief Executive Officer of Inspira, commented: “2025 marked a pivotal year for Inspira as we advanced from clinical validation into early commercial execution. Throughout 2025 and since year-end, we saw meaningful progress across multiple commercialization pathways for the INSPIRA™ ART100 system, including active clinical use at leading medical centers, advancement of a submitted quotation into a capital intake process at a leading U.S. academic medical center, and continued expansion of our commercial footprint. In parallel, we are engaged in ongoing discussions with multiple medical device companies regarding broader strategic collaboration frameworks and other potential value-creating opportunities to support the Company’s long-term commercial expansion. We also strengthened the broader foundation of the Company through continued development of HYLA™ and further expansion of our intellectual property portfolio. As we move through 2026, our focus remains on execution - advancing procurement processes, expanding clinical and commercial deployment, and converting our growing opportunity base into revenue.”
Recent Business and Operational Highlights
- Clinical Validation and Expansion in Leading Medical Centers: In April 2025, Inspira successfully treated its first patient using the ART100 system at Westchester Medical Center, marking a critical milestone in validating the system’s real-world clinical performance. Subsequent to year-end, the ART100 was deployed at additional leading medical centers in the U.S. and has alre been used in multiple clinical procedures, including lung transplant cases, further expanding the Company’s clinical footprint and demonstrating its applicability in complex, high-acuity hospital environments.
Subsequent to year-end, the Company received vendor approval enabling the ART100 to enter formal procurement pathways across a major healthcare network, where the system has since been used in lung transplant procedures at a leading medical center. In parallel, following completion of the clinical evaluation phase at a leading U.S. academic medical center, the institution advanced the submitted quotation into its capital intake process, reflecting continued progression toward formal procurement.
To support this expansion, the Company appointed U.S.-based Mike Hershkovitz, a former Johnson & Johnson senior business manager with nearly two decades of experience across U.S. and international healthcare markets, as Vice President of Global Sales. The Company is also engaged in active commercial discussions with multiple hospital systems and commercialization organizations across evaluation, deployment and procurement pathways, and expects additional deployments and procurement conversions as these processes advance.
- Commercial Traction, Procurement Progression and Scaling Infrastructure: During 2025, Inspira initiated its first commercial deployments of the ART100 system, generating initial revenues and establishing early user experience in hospital environments. Building on this foundation, the Company secured binding purchase orders totaling
$49.5 million during mid-2025, representing its first large-scale commercial commitments, with revenue expected to be primarily recognized during 2026 as these orders progress through governmental procurement and budgetary validation processes.
- Advancement of HYLA™ Blood Sensor and Platform Development: Inspira continued to advance its HYLA™ blood sensor platform during 2025 and subsequent to year-end. The Company previously reported
97.35% accuracy in clinical evaluations and has since progressed HYLA into a next-generation standalone configuration with additional parameters. This configuration is designed to enable HYLA to operate independently of the Company’s respiratory support devices and may support a broader commercial pathway upon regulatory clearance. In parallel, the Company strengthened its long-term platform positioning through continued expansion of its intellectual property portfolio, including U.S. patent approval for the INSPIRA™ ART500 core technology, extending protection through at least 2043.
- Strategic Evaluation and Portfolio Optimization: In January 2026, the Company announced that it had entered into a non-binding term sheet with Bio-View Ltd. outlining the principal terms of a proposed acquisition of an advanced liquid biopsy diagnostics business. Following further evaluation, the Company determined not to proceed with the proposed transaction and terminated its previously disclosed term sheet. The Company is currently evaluating strategic alternatives, including opportunities that it believes may offer a more compelling path to generating significant shareholder value, and will provide updates as appropriate.
Financial Results for the Year Ended December 31, 2025
Revenues: For the twelve months ended December 31, 2025, the Company recognized approximately
Research and development expenses for the twelve months ended December 31, 2025, were
General and administrative expenses increased to
Sales and marketing expenses decreased to
Total operating expenses for the twelve months ended December 31, 2025, were
Net loss was
Cash and cash equivalents and deposits totaled
As a result, the Company believes that due to the net proceeds from the offering and from certain amendments to existing warrants that are now classified as equity, it currently satisfies the minimum stockholder’s equity requirement of
Financial liabilities at fair value totaled
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential benefits of its products, its 2026 focus of advancing procurement processes, expanding clinical and commercial deployment, and converting its growing opportunity base into revenue, the use of the ART100 in multiple leading medical centers in the U.S. reflects the ART100’s applicability in complex, high-acuity hospital environments, that it is engaged in active commercial discussions with multiple hospital systems and commercialization organizations across evaluation, deployment and procurement pathways, and expects additional deployments and procurement conversions as these processes advance, that it is currently evaluating strategic alternatives, including opportunities that it believes may offer a more compelling near-term path to shareholder value, and the timing of such updates, that the funds raised subsequent to year end is intended to support continued commercial execution, ongoing operations and strategic initiatives in 2026 and its belief that it is in compliance with Nasdaq’s shareholders’ equity requirement for continued listing on Nasdaq. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
Investor Relations Contact
Arx Investor Relations
North American Equities Desk
inspira@arxhq.com
STATEMENTS OF BALANCE SHEETS
(US dollars in thousands)
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | 3,159 | 5,111 | ||||||
| Deposits | - | 668 | ||||||
| Other current assets | 517 | 587 | ||||||
| Inventory | 735 | 444 | ||||||
| Total current assets | 4,411 | 6,810 | ||||||
| Non-Current Assets: | ||||||||
| Right of use assets, net | 478 | 761 | ||||||
| Property, plant and equipment, net | 452 | 499 | ||||||
| Total non-current assets | 930 | 1,260 | ||||||
| Total Assets | 5,341 | 8,070 | ||||||
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Trade accounts payables | 107 | 154 | ||||||
| Other accounts payable | 1,349 | 1,364 | ||||||
| Lease liabilities | 286 | 277 | ||||||
| Financial Liabilities at Fair Value | 1,082 | 1,575 | ||||||
| Total current liabilities | 2,824 | 3,370 | ||||||
| Non-Current Liabilities: | ||||||||
| Lease liabilities | 194 | 378 | ||||||
| Total non- current liabilities | 194 | 378 | ||||||
| Shareholders’ Equity: | ||||||||
| Share capital and additional paid in capital | 82,117 | 70,896 | ||||||
| Accumulated deficit | (79,794 | ) | (66,574 | ) | ||||
| Total Shareholder’s Equity | 2,323 | 4,322 | ||||||
| Total Liabilities and Shareholders’ Equity | 5,341 | 8,070 | ||||||
STATEMENTS OF COMPREHENSIVE LOSS
(US dollars in thousands)
| Year ended December 31, 2025 | Year ended December 31, 2024 | |||||||
| Revenues | 289 | - | ||||||
| Cost of revenues | 287 | - | ||||||
| Gross Profit | 2 | - | ||||||
| Research and development expenses | 7,496 | 6,323 | ||||||
| General and administrative expenses | 5,532 | 4,185 | ||||||
| Sales and marketing expenses | 588 | 754 | ||||||
| Other expenses | 9 | 5 | ||||||
| Operating loss | 13,623 | 11,267 | ||||||
| Interest Income from deposits | (64 | ) | (172 | ) | ||||
| Finance expenses(income), net | (339 | ) | (42 | ) | ||||
| Loss before tax | 13,220 | 11,053 | ||||||
| Taxes on income | - | - | ||||||
| Total comprehensive loss for the period | 13,220 | 11,053 | ||||||
For More Financial Information:
For a comprehensive understanding of the Company’s financial reports and related management’s discussion and analysis for applicable periods, please review the company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, available on the company’s EDGAR profile at https://www.sec.gov/edgar
FAQ
How much revenue did Inspira (IINN) report for full-year 2025?
What is the status of the $49.5 million purchase orders for Inspira (IINN)?
How did Inspira strengthen its cash position after year-end 2025 (IINN)?
What clinical progress did Inspira report for the ART100 system (IINN)?
What progress did Inspira report on the HYLA blood sensor platform (IINN)?
Does Inspira (IINN) meet Nasdaq listing requirements after recent actions?
